Compare CULP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | DTIL |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | N/A | 67 |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 128.8M |
| IPO Year | 1994 | 2019 |
| Metric | CULP | DTIL |
|---|---|---|
| Price | $3.04 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 19.3K | ★ 176.0K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | $213,237,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | $34.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.10 | $3.53 |
| 52 Week High | $5.64 | $8.82 |
| Indicator | CULP | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 66.31 |
| Support Level | N/A | $4.66 |
| Resistance Level | $3.60 | $5.19 |
| Average True Range (ATR) | 0.17 | 0.30 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 8.00 | 74.57 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.